Original Research
Accepted on 13 May 2026
Economic Value of Finotonlimab Plus Bevacizumab Versus Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma in China and the United States
in Health Economics
Original Research
Accepted on 13 May 2026
in Health Economics
Original Research
Accepted on 13 May 2026
in Health Economics
Case Report
Accepted on 13 May 2026
in Head and Neck Cancer
Original Research
Accepted on 13 May 2026
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 13 May 2026
in Cancer Immunity and Immunotherapy
Methods
Accepted on 13 May 2026
in Physical Oceanography
Original Research
Accepted on 13 May 2026
in Intensive Care Medicine and Anesthesiology
Original Research
Accepted on 13 May 2026
in Integrative Genetics and Genomics
Original Research
Accepted on 13 May 2026
in Clinical and Diagnostic Microbiology and Immunology
Review
Accepted on 13 May 2026
in Biogeography and Macroecology
Original Research
Accepted on 13 May 2026
in Marine Pollution
Original Research
Accepted on 13 May 2026
in Plant Physiology
Correction
Accepted on 13 May 2026
in Animal Behavior and Welfare
Editorial
Accepted on 13 May 2026
in Adaptive & Innate Immunity in Infection
Case Report
Accepted on 13 May 2026
in Otorhinolaryngology - Head and Neck Surgery
Original Research
Accepted on 13 May 2026
in Cancer Genetics